SIRPant Immunotherapeutics
PrivateLast Round
Series B
Jan 22, 2024
Total Funding Raised
$52.99M
Company Overview
SIRPant Immunotherapeutics is a biotechnology company specializing in cancer-specific immunotherapy that utilizes adoptive cell therapy to generate tumor-specific T-cells for enhanced treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SIRPant Immunotherapeutics Comps
Public and private peers based on sector, stage, and business model.
SIRPant Immunotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 22, 2024 | ||||
| Grant | Sep 1, 2023 | ||||
| Series A | Jul 23, 2021 |
SIRPant Immunotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| BIOS Equity Partners III, L.P. | Series A |
| BioAdvance Capital | Series A |
| Biolocity | Series B |
| Bios Partners | Series B |
SIRPant Immunotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SIRPant Immunotherapeutics's valuation, stock price, and market status.
